An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys
A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects With HBeAg Positive and HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS(R) (Peginterferon Alfa-2a 40KD)
Sponsor: Hoffmann-La Roche
This observational or N/A phase trial investigates Hepatitis B, Chronic and is currently completed. Hoffmann-La Roche leads this study, which shows 13 recorded versions since 2009 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Completed
-
Dec 2025 — Feb 2026 [monthly]
Completed
-
Oct 2025 — Dec 2025 [monthly]
Completed
-
Sep 2025 — Oct 2025 [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
▶ Show 8 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Sep 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Sep 2020 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
May 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — May 2017 [monthly]
Completed NA
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aix-en-Provence, France , Al Mansurah, Egypt , Amiens, France , Amman, Jordan , Angers, France , Anyang, South Korea , Argenteuil, France , Auckland, New Zealand , Avignon, France , Bandung, Indonesia and 162 more locations